Drug
Cafelkibart clinical trials
- studies test it
- 3
- open now
- 3
- in phase 3
- 0
- first study started
- 2024
Keep track of what changes. Save the cafelkibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
LaNova Medicines Limited (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Toripalimab (1) · Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 (1) · Sintilimab (1) · Anti-CTLA-4 Monoclonal Antibody IBI310 (1) · Penpulimab (1) · Oxaliplatin (1) · Capecitabine (1) · Tislelizumab (1)
Studies
Open first, then newest update. How each study uses cafelkibart is read from its arms, and is right about nine times in ten.
Testing it · 3
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06825494Written as LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
- A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid TumoursNot yet recruitingPhase 2LaNova Medicines LimitedNCT06873854Written as LM-108
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06620822Written as LM-108+Sintilimab
Given in every arm · 5 — cafelkibart is usual care beside what is tested
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06821503Written as LM-108 injection
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06387628Written as LM-108
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsActive, not recruitingPhase 1/2LaNova Medicines LimitedNCT05518045Written as LM-108
- Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid TumoursCompletedPhase 1/2LaNova Australia Pty LimitedNCT05199753Written as LM-108
- Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursTerminatedPhase 1/2LaNova Medicines LimitedNCT05255484Written as LM-108
Codes
What other systems call cafelkibart · ClinicalTrials.gg INT018604
- UNII (FDA) YN4XWR5BUJCAFELKIBARTOne source FDA
- NCI Thesaurus C186374CafelkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YN4XWR5BUJ | CAFELKIBART | One source FDA |
| NCI Thesaurus | C186374 | Cafelkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.